Cannabis Science (CBIS) Readies To Launch New Products In California With Apothocary Genetics
COLORADO SPRINGS, Colo., Dec. 5, 2014 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. company specializing in global cannabis formulation-based drug development and consulting, is in the final stages of its preparations to launch new products throughout the California market, including extracts, oils, tinctures, tablets, and creams.
“All that’s left now is to finish work on the packaging and the labeling, and that should only take a matter of days,” said Mr. Raymond C. Dabney, Director, President & CEO and Co-Founder of Cannabis Science Inc. “The products and the formulation are there. We’re ready to launch in California and we’re excited, as I’m sure many self-medicating patients are.”
The California launch was made possible by a renegotiation of the Cannabis Science agreement with Apothecary Genetics Investments LLC. The new agreement enabled Cannabis Science to purchase and license two northern California production farms with a combined total of 51 acres. The purchase included all related equipment for cannabis cultivation and production for the state’s substantial medical cannabis market and gives Apothecary Genetics the right to sell Cannabis Science formulations throughout the State of California.
“Apothecary Genetics is state licensed and regulated, and now with our new licensing agreement we can proceed with the commercialization of our medical cannabis formulations throughout the State,” said Mr. Dabney.
Mr. Dabney said the company will provide more information about the release of its products and where they will be available in the coming days.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Raymond C. Dabney, Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
Chad S. Johnson, Esq., Director, COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
1.888.777.0658
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
